Transferring a Supplement Formula to a New Manufacturer

Moving an established supplement to a new contract manufacturer can look like a simple price comparison. In practice, the new site must reproduce a product with the right inputs, process, tests, packaging, and approved label. A formula PDF alone rarely answers those questions.

A controlled transfer brief helps both sides identify what is fixed, what can change, and what still needs evidence. It also makes a quote more useful: suppliers can price the actual work instead of assuming that a first production run is just a repeat order.

Inventory the product file before requesting proposals

Ask your current team what version of the product is actually being sold. The working file should identify:

Record	Why the new manufacturer needs it
Approved formula and serving	Defines each component, amount, and declared target
Raw-material specifications	Identifies grade, source restrictions, and acceptance criteria
Process and batch records	Shows order of addition, equipment, controls, yields, and deviations
Finished-product specification	Defines release tests, methods, and acceptance criteria
Packaging specification	Defines container, closure, film, label, coding, and case pack
Stability and complaint history	Reveals shelf-life risks and recurring field issues
Current label and claims file	Shows the approved artwork and the basis for marketed claims

List missing records openly. A brand may own the formula but lack a documented blend sequence, component supplier, or test method. The new manufacturer can help develop a transfer plan, but the unknown work must be estimated rather than buried in a “same formula” quote.

Separate formula ownership from manufacturing know-how

Confirm contract rights before sharing confidential records. Who owns the formula, process instructions, methods, and artwork? Can the current manufacturer provide a full technical package? Are there supplier agreements or proprietary premixes that the new site cannot use?

Protect the material with appropriate agreements, then share a version-controlled package. Define who may approve substitutions and which changes require written brand approval. A material that appears equivalent on an ingredient list can affect taste, density, allergen status, process yield, or test results.

Map the old process to the new equipment

Equipment names are not enough to establish equivalence. Compare scale, mixing action, hold time, transfer route, environmental controls, filling path, and cleaning constraints. For powders, evaluate flow and segregation. For liquids, address container compatibility and fill behavior. For tablets, capsules, and softgels, review the controls that are specific to the dosage form.

Decide whether the first run should be a laboratory trial, pilot, engineering batch, or commercial batch with enhanced monitoring. Set acceptance criteria before the run. Examples include blend uniformity, fill weight, appearance, seal integrity, sensory performance, and finished-product testing where relevant. The exact panel should follow the product's approved specification and risk assessment.

FDA's dietary supplement CGMP guide explains why a master manufacturing record, batch production record, specifications, quality review, and packaging controls must be aligned for U.S. dietary supplement manufacturing. The transfer should result in controlled documents at the receiving site, not an informal promise to copy a prior batch.

Reconcile the label and release plan

Do not reuse artwork automatically after a supplier, component, or process change. Check ingredient and allergen statements, Supplement Facts, net quantity, business information, directions, claims, and packaging fit for the intended market. FDA's labeling guide identifies the core statements for U.S. dietary supplement labels.

Marketing claims need their own review. Changing a formula or ingredient source may affect the evidence behind a claim even if the front panel looks unchanged. The FTC health-products guidance explains that objective claims must be truthful, not misleading, and appropriately supported before they are used.

Agree in writing on release responsibility: which tests are required, which laboratory and methods will be used, what happens to an out-of-specification result, and who authorizes the lot for distribution. “COA available” is not a complete release agreement.

Build a transition plan that protects supply

If the product is already selling, inventory and launch timing matter as much as the first new batch. Map existing finished stock, remaining packaging, critical ingredient lead times, stability work, pilot decisions, first commercial run, release testing, and freight. Decide how the brand will distinguish old and new lots in its records and customer service process.

Avoid announcing a fixed launch date before the technical file is reviewed. A trial may show that the new site needs a different material grade or package dimension. A realistic plan contains decision gates and owners, rather than an unsupported promise of an identical product by a calendar date.

Send a transfer-ready inquiry

Your first message does not need to include confidential formulas. State the product format, current stage, target market, approximate first order, packaging, desired transition window, and whether you can provide an approved technical package under an agreement. Mention any known issue with the current product that the new manufacturer must address.

Use the project brief checklist for the commercial details. HiGO's manufacturing process overview explains the project path; the quote form lets you share the project outline for a feasibility review. The team can then identify which records and trials are needed before a comparable quote and schedule are confirmed.